Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070882 | 0.97 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL29837023 | 0.97 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL24966725 | 0.97 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL24965296 | 0.97 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL23085284 | 0.93 | TSHR (0.34) | TSHRPDK2 | |
| SCHEMBL21069506 | 0.91 | TSHR (0.44) | TSHRPDK2L3MBTL1CA14HDAC1 | |
| SCHEMBL22774377 | 0.89 | TSHR (0.42) | TSHRPDK2L3MBTL1CA14HDAC1 | |
| SCHEMBL25831188 | 0.89 | TSHR (0.32) | TSHRPDK2 | |
| SCHEMBL22773993 | 0.88 | TSHR (0.41) | TSHRPDK2L3MBTL1CA14HDAC1 | |
| SCHEMBL21070118 | 0.88 | TSHR (0.41) | TSHRPDK2L3MBTL1CA14HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4634175-A1 | BENZIMIDAZOLE DERIVATIVES | Immvention Therapeutix, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020249970-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249970-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249969-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249969-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885PDK2 1509/4885L3MBTL1 1394/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885PDK2 1509/4885L3MBTL1 1394/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | TSHR 553/4885PDK2 2428/4885L3MBTL1 3922/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885PDK2 1509/4885L3MBTL1 1394/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | TSHR 450/4885PDK2 3591/4885L3MBTL1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.